News coverage about KalVista Pharmaceuticals (NASDAQ:KALV) has been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. KalVista Pharmaceuticals earned a daily sentiment score of 0.06 on Accern’s scale. Accern also gave media coverage about the specialty pharmaceutical company an impact score of 46.5637919686107 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Several equities research analysts have commented on KALV shares. BTIG Research upped their price target on KalVista Pharmaceuticals from $18.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, October 16th. ValuEngine upgraded KalVista Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, December 31st.
Shares of KalVista Pharmaceuticals (KALV) opened at $10.01 on Tuesday. KalVista Pharmaceuticals has a 12 month low of $5.48 and a 12 month high of $15.80.
ILLEGAL ACTIVITY WARNING: This news story was originally published by BBNS and is owned by of BBNS. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/kalvista-pharmaceuticals-kalv-receiving-somewhat-favorable-press-coverage-analysis-shows/1819973.html.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.